Compare Crown Castle International Corp (CCI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Novo Nordisk A/S — how do they compare? Crown Castle International Corp trades at $73.8 (market cap $31.33B), while Novo Nordisk A/S trades at $45.88 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 6.6× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.77%). Which is the better fit depends on your goals.
| CCI | NVO | |
|---|---|---|
Market Cap | $31.33B | $207.85B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $63.98 |
52-Week Low | $73.61 | $35.29 |
Enterprise Value | $53.69B | $222.55B |
Dividend Yield | 5.77% | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
